- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 347 | GlobeNewswire (Europe) | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 319 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 310 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 355 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 296 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 335 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 317 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 255 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 471 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 129,66 | -0,25 % | Can Bixlenvo Unlock New Growth for Gilead's HIV Business? | ||
| ABBVIE | 220,60 | -0,05 % | AbbVie meldet Erfolg in Phase-3-Studie mit Etentamig | Der US-Pharmakonzern AbbVie hat am Donnerstag positive Ergebnisse aus der Phase-3-Studie CERVINO mit dem Prüfpräparat Etentamig vorgelegt. Untersucht wurde die Behandlung bei Patienten mit rezidiviertem... ► Artikel lesen | |
| ABBOTT LABORATORIES | 93,36 | +0,11 % | Gewinner der Börsengeschichte: Kaum ein Deutscher kennt diese Heißzeit-Aktie - Sie brachte +3.923.693% Rendite! | © Foto: Christoph Hardt/Geisler-Fotopress - Geisler-FotopressDer US-amerikanische Anbieter von Klimalösungen Trane Technologies gilt als Profiteur des Klimawandels. Die Buy-and-Hold-Gesamtrendite liegt... ► Artikel lesen | |
| SCHOTT PHARMA | 23,050 | -1,07 % | Community-Rückblick: wO-User zum Gerresheimer-CEO-Rücktritt: "Der Röhrhoff macht den Röhrhoff." | © Foto: Christoph Reichwein - dpaGerresheimer sorgt für Diskussionen: Der überraschende Abgang von Interim-CEO Röhrhoff und schwache Quartalszahlen werfen Fragen auf. Steht der Konzern vor dem Neustart... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 77,06 | -0,44 % | Edwards Lifesciences strategy VP will leave next year | ||
| ASSEMBLY BIOSCIENCES | 31,300 | 0,00 % | Assembly Biosciences-Aktie: UBS startet Coverage mit Ziel 52 US$ - Mizuho erhöht Rating | Die Neubewertung von Assembly Biosciences gewinnt weiter an Dynamik. Nachdem Partner Gilead Sciences mit der Auswahl von GS-1179 für die Phase 2 und der möglichen Ausweitung des Programms auf Präventionsanwendungen... ► Artikel lesen | |
| PENTIXAPHARM | 1,850 | -1,60 % | Eckert & Ziegler im Fokus: Bafin prüft nach Pentixapharm-Abspaltung | ||
| FILANA THERAPEUTICS | 0,699 | 0,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 177,25 | -0,42 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation | NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today... ► Artikel lesen | |
| MEDPACE | 502,20 | -1,37 % | President & CEO Of Medpace Holdings Makes $403K Sale | ||
| ZEALAND PHARMA | 40,610 | -0,73 % | Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) | ||
| UNITED THERAPEUTICS | 416,80 | -0,76 % | United Therapeutics bid to expand nebulized Tyvaso label gets FDA review | ||
| UCB | 210,20 | -0,14 % | UCB's Bimzelx comes from out of the blue to claim August's top pharma ad spending spot | ||
| MADRIGAL PHARMACEUTICALS | 466,90 | +0,24 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,02 | -1,04 % | BridgeBio Pharma, Inc.: Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM | - Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing... ► Artikel lesen |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,315 Euro und damit +0,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.